Physician profile
Alfredo E Gonzalez
NPI 1992776116
$5,412.22
in general payments reported to CMS, 2019-2025
37 companies · $690 in 2025
The $690 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $258 · 2021: $914 · 2022: $944 · 2023: $1,022 · 2024: $601 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $73.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.46 |
| Education | $73.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,115.91 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $980.45 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $568.11 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $385.52 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $203.90 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $203.03 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $193.67 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.88 | 2021-2025 | |
| Travere Therapeutics, INC. | $165.56 | 2022-2025 | |
| Ardelyx, INC. | $161.76 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $123.53 | 2022-2025 | Livtencity |
| Medtronic, INC. | $114.24 | 2022 | |
| Nxstage Medical, INC. | $109.03 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $91.87 | 2019-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $78.75 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.30 | 2023-2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $59.23 | 2025 | |
| Outset Medical INC | $56.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.01 | 2019 | |
| Novo Nordisk INC | $46.85 | 2025 | Ozempic, Wegovy |
| Mallinckrodt Enterprises LLC | $46.22 | 2019 | |
| Kyowa Kirin, INC. | $44.65 | 2023 | Crysvita |
| Aurinia Pharma U.S., INC. | $44.20 | 2022-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $41.59 | 2022-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $37.61 | 2022 | |
| Mallinckrodt Hospital Products INC. | $37.57 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $35.81 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.95 | 2020-2023 | Ultomiris |
| Eurofins Viracor, LLC | $30.05 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $23.79 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.40 | 2023 | Keveyis |
| Amarin Pharma, INC. | $16.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.39 | 2022 | |
| Scpharmaceuticals INC. | $16.00 | 2025 | |
| Journey Medical Corporation | $14.74 | 2025 | |
| Genentech USA, INC. | $13.64 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.